Edwin Pun Hui

Dr. Edwin Pun Hui


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJeff P. Bruce
Jeff P. Bruce
Ka Fai ToKa Fai To
Ka Fai To
VLVivian Lui
Vivian Lui
GCGrace T. Y. Chung
Grace T. Y. Chung
YCYuk-Yu Chan
Yuk-Yu Chan
KLKwok Wai Lo
Kwok Wai Lo
Interplay between EBV infection and acquired genetic alterations during nasopharyngeal carcinoma (NPC) development remains vague. Here we report a comprehensive genomic analysis of 70 NPCs, combining whole-genome sequencing (WGS) of microdissected tumor cells with EBV oncogene expression to reveal multiple aspects of cellular-viral co-operation in tumorigenesis. Genomic aberrations along with EBV-encoded LMP1 expression underpin constitutive NF-κB activation in 90% of NPCs. A similar spectrum of somatic aberrations and viral gene expression undermine innate immunity in 79% of cases and adaptive immunity in 47% of cases; mechanisms by which NPC may evade immune surveillance despite its pro-inflammatory phenotype. Additionally, genomic changes impairing TGFBR2 promote oncogenesis and stabilize EBV infection in tumor cells. Fine-mapping of CDKN2A/CDKN2B deletion breakpoints reveals homozygous MTAP deletions in 32-34% of NPCs that confer marked sensitivity to MAT2A inhibition. Our work concludes that NPC is a homogeneously NF-κB-driven and immune-protected, yet potentially druggable, cancer.


4 September 2010 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
EHEdwin Pun Hui
Edwin Pun Hui
LLLinda K. S. Leung
Linda K. S. Leung
TPTerence C. W. Poon
Terence C. W. Poon
FMFrankie Mo
Frankie Mo
VCVicky T. C. Chan
Vicky T. C. Chan
ACAnthony T. C. Chan
Anthony T. C. Chan

17 March 2020 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
AKAnn D. King
Ann D. King
JWJ.K.S. Woo
J.K.S. Woo
Qi Yong Hemis AiQi Yong Hemis Ai
Qi Yong Hemis Ai
FMF.K.F. Mo
F.K.F. Mo
TSTiffany So
Tiffany So
KCKwan Chee Allen Chan
Kwan Chee Allen Chan
BACKGROUND AND PURPOSE: We evaluated modifications to our contrast-enhanced MR imaging grading system for symptomatic patients with suspected nasopharyngeal carcinoma, aimed at improving discrimination of early-stage cancer and benign hyperplasia. We evaluated a second non-contrast-enhanced MR imaging grading system for asymptomatic patients from nasopharyngeal carcinoma plasma screening programs. MATERIALS AND METHODS: Dedicated nasopharyngeal MR imaging before (plain scan system) and after intravenous contrast administration (current and modified systems) was reviewed in patients from a nasopharyngeal carcinoma–endemic region, comprising 383 patients with suspected disease without nasopharyngeal carcinoma and 383 patients with nasopharyngeal carcinoma. The modified and plain scan systems refined primary tumor criteria, added a nodal assessment, and expanded the system from 4 to 5 grades. The overall combined sensitivity and specificity of the 3 systems were compared using the extended McNemar test (a χ2 value χ(2)2> 5.99 indicates significance). RESULTS: The current, modified, and plain scan MR imaging systems yielded sensitivities of 99.74%, 97.91%, and 97.65%, respectively, and specificities of 63.45%, 89.56% and 86.42%, respectively. The modified system yielded significantly better performance than the current (χ(2)2 = 122) and plain scan (χ(2)2 = 6.1) systems. The percentages of patients with nasopharyngeal carcinoma in grades 1–2, grade 3, and grades 4–5 for the modified and plain scan MR imaging systems were 0.42% and 0.44%; 6.31% and 6.96%; and 90.36% and 87.79%, respectively. No additional cancers were detected after contrast administration in cases of a plain scan graded 1–2. CONCLUSIONS: We propose a modified MR imaging grading system that improves diagnostic performance for nasopharyngeal carcinoma detection. Contrast was not valuable for low MR imaging grades, and the plain scan shows potential for use in screening programs.

10 March 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
EHEdwin Pun Hui
Edwin Pun Hui
BMBrigette B.Y. Ma
Brigette B.Y. Ma
WLWai Kei Jacky Lam
Wai Kei Jacky Lam
KCK.C. Allen Chan
K.C. Allen Chan
FMFrankie Mo
Frankie Mo
ACAnthony T.C. Chan
Anthony T.C. Chan
Purpose: To study the dynamic changes in plasma Epstein–Barr virus (pEBV) DNA after radiotherapy in nasopharyngeal cancer (NPC). Experimental Design: We conducted a randomized controlled trial of adjuvant chemotherapy versus observation in patients with NPC who had detectable pEBV DNA at 6 weeks post-radiotherapy. Randomized patients had a second pEBV DNA checked at 6 months post-randomization. The primary endpoint was progression-free survival (PFS). Results: We prospectively enrolled 789 patients. Baseline post-radiotherapy pEBV DNA was undetectable in 573 (72.6%) patients, and detectable in 216 (27.4%) patients, of whom 104 (13.2%) patients were eligible for randomization to adjuvant chemotherapy (n = 52) versus observation (n = 52). The first post-radiotherapy pEBV DNA had a sensitivity of 0.48, specificity of 0.81, area under receiver-operator characteristics curve (AUC) of 0.65, false positive (FP) rate of 13.8%, and false negative (FN) rate of 14.4% for disease progression. The second post-radiotherapy pEBV DNA had improved sensitivity of 0.81, specificity of 0.75, AUC of 0.78, FP rate of 14.3%, and FN rate of 8.1%. Patients with complete clearance of post-radiotherapy pEBV DNA (51%) had survival superior to that of patients without post-radiotherapy pEBV DNA clearance (5-year PFS, 85.5% vs. 23.3%; HR, 9.6; P < 0.0001), comparable with patients with initially undetectable post-radiotherapy pEBV DNA (5-year PFS, 77.1%), irrespective of adjuvant chemotherapy or observation. Conclusions: Patients with NPC with detectable post-radiotherapy pEBV DNA who experienced subsequent pEBV DNA clearance had superior survival comparable with patients with initially undetectable post-radiotherapy pEBV DNA. Post-radiotherapy pEBV DNA clearance may serve as an early surrogate endpoint for long-term survival in NPC.

2 August 2004 in Cancer
Verified
Journal Article
Closed access
PDF file
Brigette Buig Yue MaBrigette Buig Yue Ma
Brigette Buig Yue Ma
SLSing F. Leungm
Sing F. Leungm
EHEdwin Pun Hui
Edwin Pun Hui
FMFrankie Mo
Frankie Mo
WKWing H. Kwan
Wing H. Kwan
ACAnthony T. C. Chan
Anthony T. C. Chan